Again, in MS patients globally considered, we found that plasma levels of HGF, Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 were significantly lower in the inflammatory (RR-MS patients) than in the progressive forms (SP-MS and PP-MS). The gene discussed is CCL2; the disease is myeloid sarcoma.